Meeting
2024 ASCO Breakthrough
Therapeutically targeting the CALR/CD47 pathway in MPN to reactivate natural immunosurveillance mechanisms within the body to enhance treatment outcomes.
Authors
Ciro Roberto Rinaldi
University of Lincoln, Lincoln, United Kingdom
Ciro Roberto Rinaldi , Matthew Simmonds , Claire Walker , Niloofar Amirian , Moradalden Musleh , Anya Megan Squires
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Thoracic Cancers,Breast Cancer,Gynecologic Cancer,Head and Neck Cancer,Hematologic Malignancies,Genetics/Genomics/Multiomics,Healthtech Innovations,Models of Care and Care Delivery,Viral-Mediated Malignancies,Other Malignancies or Topics
Sub Track
Immunotherapies
Citation
J Clin Oncol 42, 2024 (suppl 23; abstr 170)
DOI
10.1200/JCO.2024.42.23_suppl.170
Abstract #
170
Poster Bd #
G1
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Expression of CD47 and CALR in myeloproliferative neoplasms and myelodysplastic syndrome: Potential new therapeutical targets.
First Author: Ciro Roberto Rinaldi
Poster
2019 Breakthrough
Expression of CD47 and CALR in myeloproliferative neoplasms: Potential new therapeutic targets.
First Author: Ciro Roberto Rinaldi
Poster
2023 ASCO Breakthrough
Effect of ruxolitinib and magrolimab on calreticulin in myelofibrosis CD34+ cells in vitro: Proof of concept for combination therapy.
First Author: Ciro Roberto Rinaldi
Poster
2023 ASCO Annual Meeting
Effects of ruxolitinib and magrolimab on calreticulin in myelofibrosis CD34+ cells in vitro: Proof of concept for combination therapy.
First Author: Ciro Roberto Rinaldi